AYTU
What one share of Aytu Biopharma holds
Pharmaceutical Preparations
Aytu BioPharma, Inc. (“Aytu,” the “Company,” “we,” “us,” or “our”) is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients.
Aytu Biopharma’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $4.67 |
|---|---|
| Profit | −$1.16 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | $0.26 |
| Cash and investments | $2.45 |
| Debt | $1.02 |
| Book value | $3.29 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $187.83 | −$696.18 | $1.54 | −$356.44 | — | — |
| 2020 | $122.29 | −$60.28 | $0.00 | −$125.57 | — | — |
| 2021 | $78.38 | −$69.61 | $2.80 | −$33.80 | — | $100.08 |
| 2022 | $65.77 | −$74.01 | $0.00 | −$19.61 | — | $22.97 |
| 2023 | $32.16 | −$5.11 | — | −$1.54 | — | $7.13 |
| 2024 | $11.77 | −$2.86 | $0.06 | −$0.31 | — | $4.64 |
| 2025 | $10.57 | −$2.16 | $0.04 | −$0.34 | — | $2.11 |
| 2026 | $4.67 | −$1.16 | $0.00 | $0.26 | — | $3.29 |